NASDAQ · Medical - Devices

BIOLASE, Inc. (BIOL) Stock

$0.02 +27.39% NASDAQ: BIOL Healthcare

BIOLASE, Inc., along with its various divisions, operates as a global enterprise specializing in the creation, production, distribution, and sale of advanced laser systems. These technologies are specifically designed for dental professionals and their patients across the United States and internationally.

Valuation

MetricValue
Price$0.02
Market Cap$731942
P/E Ratio0.00
P/B Ratio-0.10
P/S Ratio0.01
EPS (TTM)$-16.14
52-Week High$1.94
52-Week Low$0.02
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-888.93%
ROA-58.78%
ROCE-116.19%
Gross Margin34.02%
Operating Margin-36.48%
Net Margin-41.97%
Debt/Equity-72.51
Current Ratio1.26

Annual Financials (USD)

Metric20192020202120222023
Revenue$38.0M$23.0M$39.0M$48.0M$49.0M
Operating Profit$-16.0M$-19.0M$-16.0M$-25.0M$-18.0M
Net Profit$-18.0M$-17.0M$-16.0M$-29.0M$-21.0M
EPS$-1923.95$-688.19$-273.41$-413.19$-16.14
Op Margin-41.3%-81.4%-41.1%-52.3%-36.5%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$32.0M$41.0M$55.0M$38.0M$35.0M
Total Liabilities$31.0M$31.0M$30.0M$33.0M$35.0M
Cash$6.0M$18.0M$30.0M$4.0M$7.0M
Borrowings$14.0M$18.0M$15.0M$16.0M$18.0M

Latest News

ADMA Biologics (ADMA) Faces Class Actions And Probes Over Revenue Allegations Simply Wall St. · Jul 15, 2026 As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22 CNW Group · Jul 15, 2026 ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run Simply Wall St. · Jul 15, 2026 ADMA: Lowering target price to $8.00 Argus Research · Jul 15, 2026 Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights Zacks · Jul 13, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-13.0M$-13.0M$-17.0M$-27.0M$-14.0M
Investing Cash Flow$0$0$-1.0M$-11.0M$-2.0M
Financing Cash Flow$-1.0M$12.0M$16.0M$0$3.0M
Net Cash Flow$-2.0M$12.0M$12.0M$-26.0M$2.0M
Free Cash Flow$-13.0M$-13.0M$-17.0M$-30.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.78
FCF Yield-2104.27%
Quick Ratio0.68
Interest Coverage-7.60
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACORAcorda Therapeutics, Inc. $0.66 -24.02% 0.00 $821028 0.00%
AXDXAccelerate Diagnostics, Inc. $0.03 +0.00% -0.02 $859918 0.00%
BLCMBellicum Pharmaceuticals, Inc. $0.07 -6.68% -0.09 $778326 0.00%
CYTHCyclo Therapeutics, Inc. $0.72 +0.00% -0.59 $23.59M 0.00%
GBSGBS Inc. $0.47 -1.58% -0.18 $433577 0.00%

About BIOLASE, Inc.

BIOLASE, Inc., along with its various divisions, operates as a global enterprise specializing in the creation, production, distribution, and sale of advanced laser systems. These technologies are specifically designed for dental professionals and their patients across the United States and internationally. The sophisticated laser instruments developed by BIOLASE empower a diverse array of dental specialists—including general dentists, periodontists, endodontists, and oral surgeons—to execute a broad spectrum of minimally invasive procedures. These applications range from cosmetic enhancements and restorative treatments to intricate surgical interventions. Among its core product offerings, the company provides Waterlase all-tissue dental laser systems, which are highly effective for precisely cutting both soft and hard tissues. It also supplies diode soft-tissue laser systems, utilized for procedures involving soft tissue, pain management, teeth whitening, and various other aesthetic treatments. Furthermore, the Epic Hygiene laser assists in addressing non-surgical periodontitis and enhancing overall clinical efficiency. Beyond its primary laser devices, BIOLASE also manufactures and distributes essential consumable items and accessories. This comprehensive range includes flexible fibers, specialized hand pieces, and professional teeth whitening gel kits. The company markets its products through a dedicated in-house sales team and an extensive network of distributors. Established in 1984, the organization was initially known as BIOLASE Technology, Inc., before officially changing its name to BIOLASE, Inc. in 2012. Its corporate headquarters are situated in Foothill Ranch, California.

BIOLASE, Inc. is headquartered in US.

BIOLASE, Inc. (BIOL) stock trades at $0.02 with a market capitalization of $731942. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of -0.10, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.02 and $1.94, and currently trades 99.0% below its 52-week high.

On profitability, BIOLASE, Inc. generates a return on equity (ROE) of -888.93%, return on capital employed of -116.19%, an operating margin of -36.48%, a net profit margin of -41.97%.

Official website: www.biolase.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides